# US 2021/0277046 A1 · Cyclic dinucleotides as sting agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277046 A1
- Document ID: US20210277046A1
- Status: Published application
- Kind: A1
- Application number: 17/260,886
- Filed: 2019-07-16
- Published: 2021-09-09
- Earliest claimed: 2018-07-17
- Assignees: Janssen Biotech, Inc.
- Applicants: Janssen Biotech, Inc.
- Inventors: Stuart Emanuel; Mark Richter; Peter J. Connolly; James P. Edwards; Guangyi Wang; Santhosh Kumar Thatikonda; Leonid Beigelman; Gilles Bignan; Wim Bert Griet Schepens; Marcel Viellevoye; Johannes Wilhelmus J.F. Thuring
- Web page: https://patentgrep.com/patent/US20210277046A1

## CPC

- C07H 19/207: the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
- C07H 21/02: with ribosyl as saccharide radical
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C07H 19/23: Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
- C07H 21/04: with deoxyribosyl as saccharide radical
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I), wherein R1, R1′, X1, B1, R2, R2′, B2, X2, R3, Z-M-Y, and Y1-M1-Z1 are as defined herein.

## Claims

### Claim 1

A compound of Formula (I):
wherein
B1 and B2 are, independently, b1, b2, b3, b4, b5, b6, b7, b8, b9, b10, b11, b12, b13, b14, b15, b16, b17, b18, b19, b20, b21, b22, b23, b24, b25, b26, b27, b28, b29, or b30:
R1 is hydrogen; hydroxy; fluoro; optionally substituted C1-3alkoxy; C3-6alkenyloxy; C2-6alkynyloxy; hydroxy(C1-3alkoxy); or optionally substituted C1-3alkyl;
R1′ is hydrogen, fluoro, or hydroxy; provided that when R1′ is fluoro, R1 is hydrogen or fluoro;
R2 is hydrogen; hydroxy; fluoro; optionally substituted C1-3alkoxy; C3-6alkenyloxy; C2-6alkynyloxy; hydroxy(C1-3alkoxy); or optionally substituted C1-3alkyl; and R3 is hydrogen;
or, R3 is —CH2—, and R2 is —O—; such that R2, R3 and the atoms to which they are attached form a 5-membered ring;
R2′ is hydrogen, fluoro, or hydroxy; provided that when R2′ is fluoro, R2 is hydrogen or fluoro;
R3 hydrogen, fluoro, CH3, or CH2F;
X1 and X2 are, independently, O, S, or CH2;
L and L1 are, independently, —CH2— or —CH2CH2—;
Y and Y1 are, independently, absent, O, or NH;
Z and Z1 are, independently, O or NH;
one of M and M1 is
and the other of M and M1 is
wherein:
(i) when M is
one of Y and Z is NH, and the other of Y and Z is O; and
(ii) when M1 is
one of Y1 and Z1 is NH, and the other of Y1 and Z1 is O;
(iii) when Y is absent, L is —CH2CH2, and M is
and
(iv) when Y1 is absent, L1 is absent, and M1 is
R4 is hydroxy, methyl, BH3, or —SR5; wherein:
R5 is hydrogen, —CH2OC(O)R6, —CH2OC(O)OR6, —CH2CH2SC(O)R6, or —CH2CH2S—SCH2R6, and
R6 is C6-10aryl, heteroaryl, heterocycloalkyl, C3-12cycloalkyl, or optionally substituted C1-20alkyl;
or an enantiomer, diastereomer, or pharmaceutically acceptable salt form thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 or R2 is C1-3alkoxy optionally substituted with one to seven halogen, methoxy, or optionally substituted C6-10aryl.

### Claim 3 (depends on 2)

The compound of claim 2, wherein the C6-10aryl is optionally substituted with one to two fluoro, chloro, bromo, iodo, C1-3alkoxy, C1-3alkyl, hydroxy, nitro or cyano.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1 or R2 is C1-3alkyl substituted with one to three fluoro, chloro, bromo, iodo, or hydroxy.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R1 is F.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R1 is H.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R1 is OH.

### Claim 8 (depends on 1)

The compound of claim 1, wherein R1′ is H.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R1′ is F.

### Claim 10 (depends on 1)

The compound of claim 1, wherein R2is F.

### Claim 11 (depends on 1)

The compound of claim 1, wherein R2 is H.

### Claim 12 (depends on 1)

The compound of claim 1, wherein R2 is OH.

### Claim 13 (depends on 1)

The compound of claim 1, wherein R2′ is H.

### Claim 14 (depends on 1)

The compound of claim 1, wherein R3 is H.

### Claim 15 (depends on 1)

The compound of claim 1, wherein L is CH2.

### Claim 16 (depends on 1)

The compound of claim 1, wherein L1 is CH2.

### Claim 17 (depends on 1)

The compound of claim 1, wherein M is P(O)(OH).

### Claim 18 (depends on 1)

The compound of claim 1, wherein M is P(O)(SH).

### Claim 19 (depends on 1)

The compound of claim 1, wherein M is S(O)2.

### Claim 20 (depends on 1)

The compound of claim 1, wherein M1 is S(O)2.

### Claim 21 (depends on 1)

The compound of claim 1, wherein M1 is P(O)(OH).

### Claim 22 (depends on 1)

The compound of claim 1, wherein M1 is P(O)(SH).

### Claim 23 (depends on 1)

The compound of claim 1, wherein X is O.

### Claim 24 (depends on 1)

The compound of claim 1, wherein X is CH2.

### Claim 25 (depends on 1)

The compound of claim 1, wherein X1 is O.

### Claim 26 (depends on 1)

The compound of claim 1, wherein X1 is CH2.

### Claim 27 (depends on 1)

The compound of claim 1, wherein Y is O

### Claim 28 (depends on 1)

The compound of claim 1, wherein Y is NH.

### Claim 29 (depends on 1)

The compound of claim 1, wherein Y1 is NH.

### Claim 30 (depends on 1)

The compound of claim 1, wherein Y1 is O.

### Claim 31 (depends on 1)

The compound of claim 1, wherein Z is O.

### Claim 32 (depends on 1)

The compound of claim 1, wherein Z is NH.

### Claim 33 (depends on 1)

The compound of claim 1, wherein Z1 is O.

### Claim 34 (depends on 1)

The compound of claim 1, wherein Z1 is CH2.

### Claim 35 (depends on 1)

The compound of claim 1, wherein Z1 is NH.

### Claim 36 (depends on 1)

The compound of claim 1, wherein B1 and B2 are each b6:

### Claim 37 (depends on 1)

The compound of claim 1, wherein B1 is b7 and B2 is b6

### Claim 38 (depends on 1)

The compound of claim 1, that is of the following structure:

### Claim 39 (depends on 1)

The compound of claim 1, wherein the compound is:
or a pharmaceutically acceptable salt form thereof.

### Claim 40

A compound that is:
or a pharmaceutically acceptable salt form thereof.

### Claim 41 (depends on 1)

The compound of claim 1, that is:
or a pharmaceutically acceptable salt thereof.

### Claim 42 (depends on 1)

The compound of claim 1, that is:
or a pharmaceutically acceptable salt thereof.

### Claim 43 (depends on 1)

The compound of claim 1, that is:
or a pharmaceutically acceptable salt thereof.

### Claim 44 (depends on 1)

The compound of claim 1, that is:
or a pharmaceutically acceptable salt thereof.

### Claim 45 (depends on 1)

The compound of claim 1, that is:
or a pharmaceutically acceptable salt thereof.

### Claim 46 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and at least one of a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, and a pharmaceutically acceptable diluent.

### Claim 47 (depends on 46)

The pharmaceutical composition of claim 46, wherein the composition is a solid oral dosage form.

### Claim 48 (depends on 46)

The pharmaceutical composition of claim 46, wherein the composition is a syrup, an elixir or a suspension.

### Claim 49 (depends on 1)

A method of treating a disease, syndrome, or condition modulated by STING, comprising administering to a subject in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 50 (depends on 1)

A method of treating a disease, syndrome, or condition, wherein said disease, syndrome, or condition is affected by the agonism of STING, comprising administering to a subject in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 51 (depends on 50)

The method of claim 50, wherein said disease, syndrome, or condition is cancer.

### Claim 52 (depends on 50)

The method of claim 50, wherein said cancer is melanoma, colon cancer, breast cancer, prostate cancer, lung cancer, or fibrosarcoma.

### Claim 53 (depends on 50)

The method of claim 50, wherein said disease, syndrome, or condition is a viral infection.

### Claim 54 (depends on 50)

The method of claim 50, wherein the viral infection is hepatitis B.

### Claim 55 (depends on 46)

A method of treating a disease, syndrome, or condition that is viral infection, melanoma, colon cancer, breast cancer, prostate cancer, lung cancer, or fibrosarcoma, comprising administering to a subject in need thereof a therapeutically effective amount of the composition of claim 46.

### Claim 56 (depends on 55)

The method of claim 55, wherein the viral infection is hepatitis B.

### Claim 57

(canceled)

### Claim 58

(canceled)

### Claim 59

(canceled)
